Form D · Biotechnology
Syros Pharmaceuticals, Inc.
Cambridge, MA · CIK 0001556263
Offering snapshot reported Sep 21, 2022 · SEC filing
- Reported sold
- $130M Offering amount: $130M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2022 | Initial | $129,843,346 | No comparison | 19 | SEC filing |
| Dec 17, 2020 | Initial | $90,490,000 | No comparison | 8 | SEC filing |
| Feb 9, 2018 | Amendment | $11,380,018 | $1,380,023vs Jan 17, 2018 | 1 | SEC filing |
| Jan 17, 2018 | Initial | $9,999,995 | No comparison | 1 | SEC filing |
| Oct 24, 2014 | Initial | $53,149,996 | No comparison | 16 | SEC filing |
| Apr 22, 2013 | Initial | $10,000,000 | No comparison | 3 | SEC filing |
| Aug 22, 2012 | Initial | $1,250,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $7.32M
- Finders' fees
- $0
- Form D file number
- 021-459511
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cowen and Company, LLC | None | |
| Piper Sandler & Co. | None |
Source: Form D, filed Sep 21, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar B. Afeyan | Director |
| Srinivas Akkaraju | Director |
| Mark Alles | Director |
| Stephane Bancel | Director |
| James E. Bradner | Director |
| Conely Chee | Executive |
| Douglas Cole | Director |
| Jorge Conde | Executive |
| Deborah Dunsire | Director |
| Sue Gail Eckhardt | Director |
| Marsha Fanucci | Director |
| Joseph Ferra, Jr. | Executive |
| Jason Haas | Executive |
| Amir Nashat | Director |
| Robert Nelsen | Director |
| Andrew Oh | Director |
| Eric Olson | Executive |
| Sanj Patel | Director |
| Gerald Quirk | Executive |
| David Roth | Executive |
| Vicki Sato | Director |
| Phillip Sharp | Director |
| Philip Sharp | Director |
| Nancy Simonian | Director, Executive |
| Jeremy Springhorn | Executive |
| Kristin Stephens | Executive |
| Timothy C. Tyson | Director |
| Harry Wilcox Iii | Executive |
| Peter Wirth | Director |
| Richard A. Young | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
35 Cambridge Park Drive
Cambridge, MA, 02140
Cambridge, MA, 02140